[
  {
    "ts": null,
    "headline": "Jim Cramer Discusses Eli Lilly (LLY) & Weight Loss Drugs",
    "summary": "We recently published 17 Stocks Jim Cramer Talked About. Eli Lilly and Company (NYSE:LLY) is one of the stocks that Jim Cramer talked about. Pharmaceutical giant Eli Lilly and Company (NYSE:LLY)’s shares are up by 23.5% over the past year and down by more than 1% year-to-date. Freedom Capital discussed the firm in February as […]",
    "url": "https://finnhub.io/api/news?id=63f3e44f0e73872c7c05750feb7e89d4e80c4666af2a4cc3931b62ff602b6669",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771437027,
      "headline": "Jim Cramer Discusses Eli Lilly (LLY) & Weight Loss Drugs",
      "id": 139137796,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published 17 Stocks Jim Cramer Talked About. Eli Lilly and Company (NYSE:LLY) is one of the stocks that Jim Cramer talked about. Pharmaceutical giant Eli Lilly and Company (NYSE:LLY)’s shares are up by 23.5% over the past year and down by more than 1% year-to-date. Freedom Capital discussed the firm in February as […]",
      "url": "https://finnhub.io/api/news?id=63f3e44f0e73872c7c05750feb7e89d4e80c4666af2a4cc3931b62ff602b6669"
    }
  },
  {
    "ts": null,
    "headline": "XPH’s 29% Run Looks Tempting, But The 5y Chart Is A Warning",
    "summary": "SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) exists to solve a specific problem: how do you gain broad exposure to pharmaceutical companies without the concentration risk of the largest healthcare names dominating your returns? XPH holds 57 positions with relatively even weighting—no single stock exceeds 2.12% of the portfolio. That structure delivers pure-play pharma exposure spanning large-cap ... XPH’s 29% Run Looks Tempting, But The 5y Chart Is A Warning",
    "url": "https://finnhub.io/api/news?id=1fd89613978fe2cd311acf5a38d83b8302e4dba31c141d1113b7717a06d919d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771433930,
      "headline": "XPH’s 29% Run Looks Tempting, But The 5y Chart Is A Warning",
      "id": 139138610,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) exists to solve a specific problem: how do you gain broad exposure to pharmaceutical companies without the concentration risk of the largest healthcare names dominating your returns? XPH holds 57 positions with relatively even weighting—no single stock exceeds 2.12% of the portfolio. That structure delivers pure-play pharma exposure spanning large-cap ... XPH’s 29% Run Looks Tempting, But The 5y Chart Is A Warning",
      "url": "https://finnhub.io/api/news?id=1fd89613978fe2cd311acf5a38d83b8302e4dba31c141d1113b7717a06d919d8"
    }
  },
  {
    "ts": null,
    "headline": "Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough?",
    "summary": "Structure Therapeutics Inc. is emerging in oral GLP-1 obesity drugs after Phase II success and rivalsâ setbacks. Click here for this GPCR stock update.",
    "url": "https://finnhub.io/api/news?id=5e34409ab632ba23ff83774cc5d4e091c3b6048a8d26a048614b9a7f4de54791",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771433484,
      "headline": "Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough?",
      "id": 139139290,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2256411028/image_2256411028.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Structure Therapeutics Inc. is emerging in oral GLP-1 obesity drugs after Phase II success and rivalsâ setbacks. Click here for this GPCR stock update.",
      "url": "https://finnhub.io/api/news?id=5e34409ab632ba23ff83774cc5d4e091c3b6048a8d26a048614b9a7f4de54791"
    }
  },
  {
    "ts": null,
    "headline": "J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push",
    "summary": "Feb 18 (Reuters) - Johnson & Johnson said on Wednesday it will invest more than $1 billion to build a new cell therapy facility in Pennsylvania, part of its larger plans announced last year to scale",
    "url": "https://finnhub.io/api/news?id=8e540301903a55b8bb3c63811aadf92bac21eed0b4a2e26f17417a31bbab409a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771428105,
      "headline": "J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push",
      "id": 139136581,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Feb 18 (Reuters) - Johnson & Johnson said on Wednesday it will invest more than $1 billion to build a new cell therapy facility in Pennsylvania, part of its larger plans announced last year to scale",
      "url": "https://finnhub.io/api/news?id=8e540301903a55b8bb3c63811aadf92bac21eed0b4a2e26f17417a31bbab409a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Gains as Medicare Expansion of GLP-1 Weight Loss Drugs Eases Pricing Concerns",
    "summary": "Impax Asset Management‘s “Impax US Sustainable Economy Fund” released its Q4 2025 investor letter. A copy of the letter can be downloaded here. The fund reported that equity markets remained volatile during the quarter amid concerns over elevated valuations and financing for large-scale data center investments, although the portfolio modestly outperformed the Russell 1000 benchmark […]",
    "url": "https://finnhub.io/api/news?id=fd38882d9c2da4d360e97af6dccccc39fb4b692887db4e3c76aef49dbe61164c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771427631,
      "headline": "Eli Lilly and Company (LLY) Gains as Medicare Expansion of GLP-1 Weight Loss Drugs Eases Pricing Concerns",
      "id": 139136582,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Impax Asset Management‘s “Impax US Sustainable Economy Fund” released its Q4 2025 investor letter. A copy of the letter can be downloaded here. The fund reported that equity markets remained volatile during the quarter amid concerns over elevated valuations and financing for large-scale data center investments, although the portfolio modestly outperformed the Russell 1000 benchmark […]",
      "url": "https://finnhub.io/api/news?id=fd38882d9c2da4d360e97af6dccccc39fb4b692887db4e3c76aef49dbe61164c"
    }
  },
  {
    "ts": null,
    "headline": "Will Tavalisse Continue to Drive Rigel Pharmaceuticals' Growth in 2026?",
    "summary": "RIGL's 2025 sales jump 60% to $232M, led by Tavalisse. With 2026 product sales seen at $255-$265M, can its momentum withstand rising competition?",
    "url": "https://finnhub.io/api/news?id=47c1ce359983829f6839bd9cbf639b218de4b37c62eaaa2f3de73d0335f359df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771420320,
      "headline": "Will Tavalisse Continue to Drive Rigel Pharmaceuticals' Growth in 2026?",
      "id": 139136583,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "RIGL's 2025 sales jump 60% to $232M, led by Tavalisse. With 2026 product sales seen at $255-$265M, can its momentum withstand rising competition?",
      "url": "https://finnhub.io/api/news?id=47c1ce359983829f6839bd9cbf639b218de4b37c62eaaa2f3de73d0335f359df"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Trumps Novo Nordisk In GLP-1 Race: Multi-Year Growth Prospects",
    "summary": "Eli Lilly Trumps Novo Nordisk In GLP-1 Race: Multi-Year Growth Prospects",
    "url": "https://finnhub.io/api/news?id=81852ab59789868ad40d39087494a2bf049af3ae265a7993da669ea964a274be",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771420182,
      "headline": "Eli Lilly Trumps Novo Nordisk In GLP-1 Race: Multi-Year Growth Prospects",
      "id": 139138216,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=81852ab59789868ad40d39087494a2bf049af3ae265a7993da669ea964a274be"
    }
  },
  {
    "ts": null,
    "headline": "Can LLY's Next-Gen Obesity Pipeline Sustain Growth Amid Competition?",
    "summary": "Lilly is advancing next-gen obesity drugs like oral orforglipron and retatrutide as competition heats up.",
    "url": "https://finnhub.io/api/news?id=4cba36772150fbc18a031c6a9addc7a2b929881e625b22743944ab04f1b87fc3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771417320,
      "headline": "Can LLY's Next-Gen Obesity Pipeline Sustain Growth Amid Competition?",
      "id": 139134029,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly is advancing next-gen obesity drugs like oral orforglipron and retatrutide as competition heats up.",
      "url": "https://finnhub.io/api/news?id=4cba36772150fbc18a031c6a9addc7a2b929881e625b22743944ab04f1b87fc3"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the landmark TOGETHER-PsO open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity or overweight with at least one additional weight-related comorbid condition. At 36 weeks, treatment with Taltz and Zepbound met the primary and all key secondary endpoints, delivering superio",
    "url": "https://finnhub.io/api/news?id=40d2f91f594482857caa51fe0101226a2cb3ae2f2a4a988f6d1b4abba4457a6b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771415100,
      "headline": "Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight",
      "id": 139132607,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the landmark TOGETHER-PsO open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity or overweight with at least one additional weight-related comorbid condition. At 36 weeks, treatment with Taltz and Zepbound met the primary and all key secondary endpoints, delivering superio",
      "url": "https://finnhub.io/api/news?id=40d2f91f594482857caa51fe0101226a2cb3ae2f2a4a988f6d1b4abba4457a6b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game",
    "summary": "Pfizer faces multi-year headwinds from loss of exclusivity and COVID franchise decline, but management highlights transformative M&A and pipeline optionality. Learn more on PFE stock here.",
    "url": "https://finnhub.io/api/news?id=1f217c533254f79a9c2f02e8a8a54def6f9804070b86bfe42a3995347dc1f14e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771414200,
      "headline": "Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game",
      "id": 139137080,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440985/image_1292440985.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Pfizer faces multi-year headwinds from loss of exclusivity and COVID franchise decline, but management highlights transformative M&A and pipeline optionality. Learn more on PFE stock here.",
      "url": "https://finnhub.io/api/news?id=1f217c533254f79a9c2f02e8a8a54def6f9804070b86bfe42a3995347dc1f14e"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to pay CSL $100M to license monoclonal antibody targeting IL-6",
    "summary": "The Australian company will retain rights for an end-stage kidney disease indication currently being tested in a Phase 3 trial while Lilly explores other uses.",
    "url": "https://finnhub.io/api/news?id=4ba6017a3efc6c59f3111dcb8d2a11056242162a2b55a07fc779ce69b909d417",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771413318,
      "headline": "Lilly to pay CSL $100M to license monoclonal antibody targeting IL-6",
      "id": 139137797,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Australian company will retain rights for an end-stage kidney disease indication currently being tested in a Phase 3 trial while Lilly explores other uses.",
      "url": "https://finnhub.io/api/news?id=4ba6017a3efc6c59f3111dcb8d2a11056242162a2b55a07fc779ce69b909d417"
    }
  },
  {
    "ts": null,
    "headline": "US stocks are off to their worst start versus the global market since 1995",
    "summary": "As US valuations and price-to-earnings ratios have surged, global markets have outperformed the S&P 500.",
    "url": "https://finnhub.io/api/news?id=cfe38d347cfa5d9068276ca20faa3af26afaaee566521a0e36f3f824cd829d16",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771412419,
      "headline": "US stocks are off to their worst start versus the global market since 1995",
      "id": 139132593,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As US valuations and price-to-earnings ratios have surged, global markets have outperformed the S&P 500.",
      "url": "https://finnhub.io/api/news?id=cfe38d347cfa5d9068276ca20faa3af26afaaee566521a0e36f3f824cd829d16"
    }
  },
  {
    "ts": null,
    "headline": "XLV is A $41 Billion Defensive Healthcare Play That Looks Good Until You Compare To The S&P 500",
    "summary": "Healthcare isn’t going anywhere. An aging population, chronic disease management, and breakthrough treatments ensure this sector remains essential regardless of market conditions. Health Care Select Sector SPDR Fund (NYSEARCA:XLV) offers concentrated exposure to this defensive sector, but with concentration comes tradeoffs investors must understand before allocating capital. Pure Healthcare Exposure With Mega-Cap Anchors XLV functions ... XLV is A $41 Billion Defensive Healthcare Play That Looks",
    "url": "https://finnhub.io/api/news?id=d88d9891829ddb340cf72a3b311e050a1ba7b49790128751ab2509b9b5f4faf7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771410775,
      "headline": "XLV is A $41 Billion Defensive Healthcare Play That Looks Good Until You Compare To The S&P 500",
      "id": 139132609,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Healthcare isn’t going anywhere. An aging population, chronic disease management, and breakthrough treatments ensure this sector remains essential regardless of market conditions. Health Care Select Sector SPDR Fund (NYSEARCA:XLV) offers concentrated exposure to this defensive sector, but with concentration comes tradeoffs investors must understand before allocating capital. Pure Healthcare Exposure With Mega-Cap Anchors XLV functions ... XLV is A $41 Billion Defensive Healthcare Play That Looks",
      "url": "https://finnhub.io/api/news?id=d88d9891829ddb340cf72a3b311e050a1ba7b49790128751ab2509b9b5f4faf7"
    }
  },
  {
    "ts": null,
    "headline": "An Alzheimer’s startup emerges with $175M in venture backing",
    "summary": "Backed by Wellington, Sanofi Ventures and a division of J.P. Morgan, Korsana Therapeutics is studying a treatment originally developed by hub-and-spoke biotech Paragon Therapeutics.",
    "url": "https://finnhub.io/api/news?id=7ef16e7c22a2df7fa29a55e6c2f50087eee05c05512a039485d9382885dd075f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771410174,
      "headline": "An Alzheimer’s startup emerges with $175M in venture backing",
      "id": 139137798,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Backed by Wellington, Sanofi Ventures and a division of J.P. Morgan, Korsana Therapeutics is studying a treatment originally developed by hub-and-spoke biotech Paragon Therapeutics.",
      "url": "https://finnhub.io/api/news?id=7ef16e7c22a2df7fa29a55e6c2f50087eee05c05512a039485d9382885dd075f"
    }
  },
  {
    "ts": null,
    "headline": "IXJ: Healthcare Sector Dashboard For February",
    "summary": "IXJ: Healthcare Sector Dashboard For February",
    "url": "https://finnhub.io/api/news?id=4c7217c375ec3588b7d733d67e76ed36acfbee5d367368b6809a501d5b536ff7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771408800,
      "headline": "IXJ: Healthcare Sector Dashboard For February",
      "id": 139136343,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=4c7217c375ec3588b7d733d67e76ed36acfbee5d367368b6809a501d5b536ff7"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's TOGETHER-PsO Open-label Phase 3B Trial Of Concomitant Use Of Taltz (Ixekizumab) And Zepbound (Tirzepatide) Compared To Taltz Alone For Moderate-to-severe Plaque Psoriasis And Obesity Met The Primary And All Key Secondary Endpoints",
    "summary": "At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance (PASI 100) and ≥10% weight lossIn a key secondary",
    "url": "https://finnhub.io/api/news?id=d35ad32231e2caed130c6ba0db2998806f2123b82b6b96bd1f2156860ce29ddb",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771400861,
      "headline": "Eli Lilly's TOGETHER-PsO Open-label Phase 3B Trial Of Concomitant Use Of Taltz (Ixekizumab) And Zepbound (Tirzepatide) Compared To Taltz Alone For Moderate-to-severe Plaque Psoriasis And Obesity Met The Primary And All Key Secondary Endpoints",
      "id": 139135681,
      "image": "",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance (PASI 100) and ≥10% weight lossIn a key secondary",
      "url": "https://finnhub.io/api/news?id=d35ad32231e2caed130c6ba0db2998806f2123b82b6b96bd1f2156860ce29ddb"
    }
  },
  {
    "ts": null,
    "headline": "CSL Enters Into An Exclusive Licensing Agreement With Eli Lilly, Granting Certain Rights To Develop And Commercialize Clazakizumab For An Upfront Payment Of $100M And Potential Milestone Payments, As Well As Sales-based Royalties",
    "summary": "Under the terms of the agreement, CSL will retain exclusive rights to develop and commercialise clazakizumab for the prevention of cardiovascular events in patients with end-stage kidney disease (ESKD). CSL is",
    "url": "https://finnhub.io/api/news?id=5adff542d018773d930ee097e56c66fe2da51ab310e92a1a4ccda2726fcc7012",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771390945,
      "headline": "CSL Enters Into An Exclusive Licensing Agreement With Eli Lilly, Granting Certain Rights To Develop And Commercialize Clazakizumab For An Upfront Payment Of $100M And Potential Milestone Payments, As Well As Sales-based Royalties",
      "id": 139135682,
      "image": "",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "Under the terms of the agreement, CSL will retain exclusive rights to develop and commercialise clazakizumab for the prevention of cardiovascular events in patients with end-stage kidney disease (ESKD). CSL is",
      "url": "https://finnhub.io/api/news?id=5adff542d018773d930ee097e56c66fe2da51ab310e92a1a4ccda2726fcc7012"
    }
  }
]